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This volume contains papers presented at the second Frontiers in
Health Policy Research Conference, held on 11 June 1998, in Be-
thesda, Maryland. The goal of this conference, like the one held the
year before, was to bring together academic economists investigating
topics in health policy, and journalists, researchers, legislative staff,
and other government officials whose work directly touches upon
health policy. This series of conferences is designed to promote dis-
cussion and communication among these groups, helping to ensure
that the results of ongoing policy-relevant research conducted by
leading health economists will be known to a broader community
that could incorporate the information into health policy.
The work reported in this volume addresses a set of issues that
have grown more important and timely as turmoil in health care
markets and growth in the number of elderly Americans continues:
the productivity of health care; the effects of managed care on costs
and outcomes of health care; the implications of the rise of for-profit
health care providers; and the costs of medical care at the end of life.
The commonplace observation that the United States spends more
per capita on health care than any other country leads inevitably to
the question: do U.S. expenditures for health care represent "good
value" or are they wasteful? There is some evidence to support both
answers to this question; many observers decry wasteand excess in
American health care, but others point to the wide availability of
"high-tech" health services that are costly yet appear to be effec-
tive. The truth may lie somewhere between these two views, but
health care productivity, especially at the national level, defies easy
measurement.
In an ambitious effort to answer this question, Elizabeth Richard-
son and David Cutler compare measures of health and illness inthexii Tnt roducfion
United States in 1950, 1970, and 1990. They perform a cost-benefit
analysis to assess the dollar value of the changes in health that
occurred over the decades. Typical measures of population health,
such as life expectancy, are narrowly defined, and may not be good
measures of the quality of health care. Life expectancy at birth, for
example, is highly sensitive to changes in infant mortality rates,
which themselves change with the age of the mother, whether she
smokes, and several other aspects of maternal behavior and the so-
cial environment. Cutler and Richardson propose broader measures
of health that enable them to produce economic benchmarks.
Their chief measure of health status, "health capital," is a global
measure of health-related well-being that is sensitive to changes in
quality of life as well as mortality. They estimate the changing
amount of health capital, and its value, by combining national statis-
tics from several sources. They also place dollar values on changes in
health capital, enabling them to determine the benefits of rising
health expenditures over time have been commensurate with their
costs. Their provocative findingswhich suggest that some of the
health expenditure growth has contributed to improvements in health
capital, and may represent a very good valueand conclusions will
surely stimulate more debate and research in this area.
The early years covered in Cutler and Richardson's analysis apply
to a time when there was little managed care in much of the United
States, and the environment for new medications and medical proce-
dures was "technology-friendly." The growth of managed care may,
according to some commentators, have brought the technology-
friendly era of U.S. health care to a close. They claim that greater
price sensitivity in the purchase of health care has made the returns
to investments in innovative medical technologies smaller and less
certain. Under traditional fee-for-service (indemnity) health insur-
ance, neither consumers of health care nor the physicians and hospi-
tals providing care had an incentive to limit health services. Under
managed care, particularly when it takes the form of capitation, pro-
viders may face financial penalties for expenditures on the care of
their patients. Some studies have found that managed care did indeed
slow technology adoption, but others reported that managed care
had no effect. Laurence Baker and Joanne Spetz track changes in the
dissemination of expensive, specialized services like cardiac catheter-
ization, organ transplantation, and magnetic resonance imaging in
specific hospital markets. To do so, they develop an index of technol-Infroduchon xiii
ogy availability in U.S. hospitals and implement amarket-specific
measure of managed care penetration to assess the impact of man-
aged care on technology adoption between 1983 and 1993.
Unlike previous investigators, they seek to measure the effects of
managed care on the dissemination of technologies overall, rather
than specific technologies. Their findings suggest that managed care
does not have uniform effects on technology adoption, apparently
varying with time and affecting the adoption of some technologies
more than others.
The spread of managed care is only part of the changing organiza-
tion of health care markets. Other striking changes are the consolida-
tion of health care providers and the expansion of for-profit hospitals
and other health care providers, which are subject to different rules
and tax treatments than traditional providers. Takeovers of non-
profits, mergers, and investigation of billing practices are among the
topics that have come to public attention in recent years. These events
have reawakened interest in a question that regulators, lawyers,
and economists have long discussed: how does the performance of
for-profit and not-for-profit hospitals compare? Do different missions
truly lead to different behaviors and differences in community ser-
vice? Frank Sloan, Gabriel Picone, Donald Taylor, and Shin-Yi Chou
investigate these questions, focusing on the effects of not-for-profit
status on costs and quality of care. They explore outcomes of elderly
Medicare beneficiaries who have suffered from one of four major
acute health problems: hip fracture, stroke, coronary heart disease, or
congestive heart failure. They investigate whether the ownership
status of the hospital in which the Medicare beneficiary is admitted
for one of these conditions affects either health or economic outcomes.
Sloan and colleagues apply methods to distinguish the effects of
not-for-profit status and other closely associated hospital character-
istics, such as the hospital's teaching status. Among their findings are
that Medicare beneficiaries admitted to major teaching hospitals have
lower mortality rates than those admitted to other hospitals, and that
Medicare payments for home health care and physicians' services
are greater for patients discharged from for-profithospitals. These
findings suggest for-profit hospitals have been relatively adept at
responding to shifting financial incentives under Medicare, which
increasingly favor the provision of home health and other nonhospi-
tal services. They also raise a provocative question: is the growingxiv Introduction
popularity of for-profit hospitals compromising the quality of care
while increasing costs?
Concern about changes in the composition of health care providers
arises not only from for-profit status, but also from consolidation and
mergers, which can occur among not-for-profit organizations as well
as for-profits. Legal battles over proposed mergers have been promi-
nent in recent years. Merging institutions often claim that consolida-
tion is necessary to achieve productive efficiency, eliminating dupli-
cative services and excessive administrative costs. Critics claim that
mergers are primarily a vehicle to increase the market powers of
hospitals and hospital networks. If this claim is true, consolidation
increases revenues to providers but does not lower costs or improve
other aspects of performance. To evaluate the most important con-
sequences of consolidation, Daniel Kessler and Mark McClellan
apply principles of merger evaluation to hospital markets. Such prin-
ciples can be unusually difficult to apply to health care markets, be-
cause the geographic extent of the market varies with the specific
service and other hard-to-measure characteristics, and the products
and services themselves are not easily defined. Thus standard tests of
market concentration do not readily apply in health care markets.
The presence of health insurance, which subsidizes care, and differ-
ences between the information available to health care providers
means that standard tests for competition do not have the same im-
plications as in markets for other goods and services.
Kessler and McClellan describe innovative methods for addressing
these challenges. After developing measures of market concentration
suitable for hospitals, they assess whether changes in concentration,
which reflect loss of competition, are associated with improvement or
worsening outcomes. Their results have implications for antitrust
regulation of mergers, suggesting that mergers have complex but
potentially worrisome effects.
For many years, concerns about their disproportionately high
health care expenditures have directed interest toward Medicare re-
cipients at the end of life. Average expenditures for Medicare recipi-
ents in the final year of life are about six times as great as average for
beneficiaries. Is much of this care "futile"? Concern about the appro-
priateness of typical hospital care for persons with diseases that ap-
pear to be fatal has also stimulated changes in reimbursement for
and availability of end-of-life services. In the past, Medicare benefi-
ciaries usually died in an acute care hospital after an extended periodof time, or at home with minimal formal health care services. But in
recent years, Medicare reimbursement procedures and other changes
have led to greatly increased use of Medicare-covered home health
care and hospice services. Hospice care, like much home health and
nonacute hospital care, is designed to meet the needs of dying pa-
tients, who are known to generate disproportionately large costs of
care. How has use of these services by dying Medicare beneficiaries
changed over time? How has it varied by disease? Does recent expe-
rience suggest that these services have helped save the Medicare
program money by displacing hospital care and other costly services?
To address these questions, Thomas MaCurdy, Mark McClellan,
and I linked Medicare claims files from 1988 to 1995, examining
trends in the location of death, days of use of services, and expendi-
tures for the care of beneficiaries in the final months of life. We sepa-
rately examine trends in the treatment of beneficiaries with common
diseases in which death is predictable and occurs over a period of
months (e.g., lung cancer) and in which death is often sudden (e.g.,
heart attack).
Our findings suggest that services targeted toward dying patients
may have substituted for acute care services, like hospitals, but only
to a limited extent. There is little evidence from our study that liber-
alization of benefits for nonhospital care results in savings to the
Medicare program.
As these studies demonstrate, a closer look at the data can give a
nuanced picture of health care markets. That picture often casts
doubt upon the conventional wisdom. As we confront the ongoing
challenges of rising health care expenditures and projected Medicare
program deficits, such information can contribute greatly to the
policy discussion.
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